These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2290 related articles for article (PubMed ID: 22735384)

  • 41. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
    Chapman PB; Hauschild A; Robert C; Haanen JB; Ascierto P; Larkin J; Dummer R; Garbe C; Testori A; Maio M; Hogg D; Lorigan P; Lebbe C; Jouary T; Schadendorf D; Ribas A; O'Day SJ; Sosman JA; Kirkwood JM; Eggermont AM; Dreno B; Nolop K; Li J; Nelson B; Hou J; Lee RJ; Flaherty KT; McArthur GA;
    N Engl J Med; 2011 Jun; 364(26):2507-16. PubMed ID: 21639808
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
    Grob JJ; Amonkar MM; Martin-Algarra S; Demidov LV; Goodman V; Grotzinger K; Haney P; Kämpgen E; Karaszewska B; Mauch C; Miller WH; Millward M; Mirakhur B; Rutkowski P; Chiarion-Sileni V; Swann S; Hauschild A
    Ann Oncol; 2014 Jul; 25(7):1428-1436. PubMed ID: 24769640
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF
    Fujiwara Y; Yamazaki N; Kiyohara Y; Yoshikawa S; Yamamoto N; Tsutsumida A; Nokihara H; Namikawa K; Mukaiyama A; Zhang F; Tamura T
    Invest New Drugs; 2018 Apr; 36(2):259-268. PubMed ID: 28879519
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for
    Dummer R; Long GV; Robert C; Tawbi HA; Flaherty KT; Ascierto PA; Nathan PD; Rutkowski P; Leonov O; Dutriaux C; Mandalà M; Lorigan P; Ferrucci PF; Grob JJ; Meyer N; Gogas H; Stroyakovskiy D; Arance A; Brase JC; Green S; Haas T; Masood A; Gasal E; Ribas A; Schadendorf D
    J Clin Oncol; 2022 May; 40(13):1428-1438. PubMed ID: 35030011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
    Gibney GT; Zager JS
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
    Long GV; Grob JJ; Nathan P; Ribas A; Robert C; Schadendorf D; Lane SR; Mak C; Legenne P; Flaherty KT; Davies MA
    Lancet Oncol; 2016 Dec; 17(12):1743-1754. PubMed ID: 27864013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
    Syeda MM; Wiggins JM; Corless BC; Long GV; Flaherty KT; Schadendorf D; Nathan PD; Robert C; Ribas A; Davies MA; Grob JJ; Gasal E; Squires M; Marker M; Garrett J; Brase JC; Polsky D
    Lancet Oncol; 2021 Mar; 22(3):370-380. PubMed ID: 33587894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.
    Lau DK; Andrews MC; Turner N; Azad AA; Davis ID; Cebon JS
    Melanoma Res; 2014 Apr; 24(2):144-9. PubMed ID: 24463460
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dabrafenib.
    Kainthla R; Kim KB; Falchook GS
    Recent Results Cancer Res; 2014; 201():227-40. PubMed ID: 24756796
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
    Long GV; Dummer R; Hamid O; Gajewski TF; Caglevic C; Dalle S; Arance A; Carlino MS; Grob JJ; Kim TM; Demidov L; Robert C; Larkin J; Anderson JR; Maleski J; Jones M; Diede SJ; Mitchell TC
    Lancet Oncol; 2019 Aug; 20(8):1083-1097. PubMed ID: 31221619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
    Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski C; Cabanillas ME; Urbanowitz G; Mookerjee B; Wang D; Rangwala F; Keam B
    J Clin Oncol; 2018 Jan; 36(1):7-13. PubMed ID: 29072975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
    Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
    Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
    Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
    Schadendorf D; Amonkar MM; Stroyakovskiy D; Levchenko E; Gogas H; de Braud F; Grob JJ; Bondarenko I; Garbe C; Lebbe C; Larkin J; Chiarion-Sileni V; Millward M; Arance A; Mandalà M; Flaherty KT; Nathan P; Ribas A; Robert C; Casey M; DeMarini DJ; Irani JG; Aktan G; Long GV
    Eur J Cancer; 2015 May; 51(7):833-40. PubMed ID: 25794603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
    Falchook GS; Long GV; Kurzrock R; Kim KB; Arkenau TH; Brown MP; Hamid O; Infante JR; Millward M; Pavlick AC; O'Day SJ; Blackman SC; Curtis CM; Lebowitz P; Ma B; Ouellet D; Kefford RF
    Lancet; 2012 May; 379(9829):1893-901. PubMed ID: 22608338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dabrafenib in the treatment of advanced melanoma.
    Medina T; Amaria MN; Jimeno A
    Drugs Today (Barc); 2013 Jun; 49(6):377-85. PubMed ID: 23807941
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
    Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
    Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dabrafenib plus trametinib in patients with BRAF
    Wen PY; Stein A; van den Bent M; De Greve J; Wick A; de Vos FYFL; von Bubnoff N; van Linde ME; Lai A; Prager GW; Campone M; Fasolo A; Lopez-Martin JA; Kim TM; Mason WP; Hofheinz RD; Blay JY; Cho DC; Gazzah A; Pouessel D; Yachnin J; Boran A; Burgess P; Ilankumaran P; Gasal E; Subbiah V
    Lancet Oncol; 2022 Jan; 23(1):53-64. PubMed ID: 34838156
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib.
    Azer MW; Menzies AM; Haydu LE; Kefford RF; Long GV
    Cancer; 2014 Feb; 120(4):530-6. PubMed ID: 24496868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 115.